Painful and non-painful chemotherapy-induced peripheral neuropathy and quality of life in colorectal cancer survivors: results from the population-based PROFILES registry

C. S. Bonhof 1,2 & H. R. Trompetter 1 & G. Vreugdenhil 3 & L. V. van de Poll-Franse 1,2,4 & F. Mols 1,2

Received: 6 November 2019 / Accepted: 27 March 2020
© The Author(s) 2020

Abstract

Purpose This study aims to (1) examine the prevalence of painful versus non-painful chemotherapy-induced peripheral neuropathy (CIPN) among long-term colorectal cancer (CRC) survivors, (2) identify sociodemographic, clinical, and psychological factors associated with painful and non-painful CIPN, and (3) examine the associations of painful CIPN with health-related quality of life (HRQoL) in comparison with non-painful CIPN, i.e., numbness/tingling.

Methods All CRC survivors diagnosed between 2000 and 2009 as registered by the population-based Netherlands Cancer Registry (Eindhoven region) were eligible for participation. Chemotherapy-treated survivors (n = 477) completed questions on CIPN (EORTC QLQ-CIPN20) and HRQoL (EORTC QLQ-C30).

Results Painful CIPN was reported by 9% (n = 45) of survivors and non-painful CIPN was reported by 22% (n = 103). Time since diagnosis was related to painful CIPN, and time since diagnosis, a higher disease stage, osteoarthritis, and more anxiety symptoms were related to non-painful CIPN. Finally, survivors with painful CIPN reported a worse global quality of life and worse physical, role, cognitive, and social functioning compared to survivors with non-painful CIPN and those without any sensory CIPN. No differences were found between survivors with non-painful CIPN and those without sensory CIPN.

Conclusions It seems that painful CIPN must be distinguished from non-painful CIPN, as only painful CIPN was related to a worse HRQoL. Future research is needed to examine whether painful CIPN must be distinguished from non-painful CIPN regarding predictors, mechanisms, and treatment.

Keywords Chemotherapy-induced peripheral neuropathy • Colorectal cancer • Health-related quality of life • Numbness • Pain • Tingling

Introduction

Chemotherapy has contributed significantly to the increased survival rates in colorectal cancer (CRC) [1]. However, patients frequently live with the long-term side effects of this treatment. Chemotherapeutic agents commonly used in the treatment of CRC are highly toxic to the peripheral nervous system. As a result, patients often develop chemotherapy-induced peripheral neuropathy (CIPN) [2]. CIPN most commonly presents as sensory neuropathy, with symptoms such as tingling, numbness, and burning pain in the hands or feet in a characteristic stocking-glove distribution [2]. Unfortunately, there are currently no agents available for the prevention or treatment of CIPN, and so, dose reduction and even cessation of treatment are often necessary to prevent severe CIPN. After chemotherapy, CIPN symptoms often improve or even disappear, but it is a chronic issue for about 30% of patients [3].
A recent review showed that CIPN severely impacts patients’ health-related quality of life (HRQoL) [4]. In a previous PROFILES study using the same sample as the current study, it was found that only sensory neuropathy symptoms significantly distinguished chemotherapy-treated survivors from those who did not receive chemotherapy and that these symptoms were associated with worse scores on all the EORTC QLQ-C30 scales [5]. However, sensory neuropathy consists of a broad range of symptoms, and little is known about the specific sensory neuropathy symptoms and their independent impact on HRQoL. In the previously mentioned PROFILES study, it was shown that only the sensory neuropathy symptoms tingling, numbness, and shooting or burning pain were more often reported by survivors with chemotherapy compared to survivors who did not receive chemotherapy [5]. While numbness and tingling are found to be highly correlated [6, 7], correlations between painful CIPN and either numbness or tingling appear to be much weaker [7]. Also, severe numbness and tingling commonly exist without neuropathic pain symptoms, while the reverse is not common [7, 8]. These findings indicate that painful CIPN must be evaluated separately from non-painful CIPN symptoms, such as numbness and tingling.

In diabetes research, studies on diabetic peripheral neuropathy (DPN) already make an explicit distinction between painful and non-painful DPN. Pain is the main symptom causing patients with DPN to seek help [9] and results in more severe impairments in HRQoL. In the previously mentioned PROFILES study, it was shown that only the sensory neuropathy symptoms tingling, numbness, and shooting or burning pain were more often reported by survivors with chemotherapy compared to survivors who did not receive chemotherapy [5]. While numbness and tingling are found to be highly correlated [6, 7], correlations between painful CIPN and either numbness or tingling appear to be much weaker [7]. Also, severe numbness and tingling commonly exist without neuropathic pain symptoms, while the reverse is not common [7, 8]. These findings indicate that painful CIPN must be evaluated separately from non-painful CIPN symptoms, such as numbness and tingling.

In cancer research, studies on diabetic peripheral neuropathy (DPN) already make an explicit distinction between painful and non-painful DPN. Pain is the main symptom causing patients with DPN to seek help [9] and results in more severe impairments in HRQoL compared to non-painful DPN [10, 11]. In cancer research, few studies have focused on the difference between painful and non-painful CIPN. A study among patients treated with adjuvant oxaliplatin or docetaxel found that among patients treated with docetaxel, those with persistent pain had significantly less improvement in anxiety and depression over time than those without persistent pain [12]. Another study among patients with colorectal, breast, lung, or prostate cancer showed that baseline neuropathic pain, but not numbness and tingling, was associated with more than twice the odds of significantly declining HRQoL in CRC patients, but not in those with other cancer types [13]. However, these studies have only examined the effect of painful versus non-painful CIPN on patient-reported outcomes up to 1 year after diagnosis, while it is unknown whether the effect is still present among long-term survivors.

Extending our knowledge on the difference between painful and non-painful CIPN seems warranted, as it could help future trials on the treatment of CIPN to determine its specific target. In addition, it is needed to identify those at high risk of developing a low HRQoL. Furthermore, gaining more insight into the correlates of (non-)painful CIPN is important to develop personalized management of CIPN. Therefore, the aims of this study were to (1) examine the prevalence of painful versus non-painful (i.e., numbness and tingling) peripheral neuropathy symptoms in chemotherapy-treated CRC survivors 2–12 years after diagnosis, (2) identify sociodemographic, clinical, and psychological factors (i.e., anxiety and depressive symptoms) associated with the presence of painful and non-painful CIPN, and (3) examine the associations of painful CIPN with HRQoL in comparison with non-painful CIPN.

Methods

Settings and participants

Details of the data collection process have previously been described [5]. In the current study, additional details of clinical characteristics were available, due to the regular updates of our cancer registry. The survey was set up in December 2010, and patients who were eligible for participation were selected from the Netherlands Cancer Registry, which routinely collects data from all individuals newly diagnosed with cancer in the Netherlands [14]. For this study, all individuals from the Eindhoven region (>2 million inhabitants) who were diagnosed with CRC between 2000 and 2009 were eligible for participation. Survivors who had cognitive impairment, who died prior to the start of the study or were terminally ill, those with carcinoma in situ, those already included in another study, and those with unverifiable addresses were excluded. One year later, the second data collection wave took place. For this study, data from this second wave was used, as it included a questionnaire on CIPN. At this time, patients were diagnosed 2–12 years ago. This study was approved by a certified medical ethics committee. All patients signed informed consent.

Data collection

Data collection was performed within PROFILES (Patient Reported Outcomes Following Initial Treatment and Long Term Evaluation of Survivorship), a registry for the physical and psychosocial impact of cancer and its treatment [15]. Eligible CRC survivors were informed of the study via a letter from their (ex-) attending specialist. A reminder letter was sent to non-respondents within 2 months.

Study measures

Sociodemographic and clinical characteristics

Survivor’s sociodemographic (i.e., age, sex) and clinical information (e.g., date of diagnosis, tumor stage, and treatment) was obtained from the NCR. The adapted Self-administered Comorbidity Questionnaire (SCQ) [16] was used to assess comorbidity at time of the study. Questions on partner status and educational level were added to the questionnaire.
Psychological factors

Symptoms of anxiety and depression were assessed with the Hospital Anxiety and Depression Scale (HADS) [17]. It consists of 14 items: 7 items measure depressive symptoms and the other 7 items measure anxiety. Items are answered on a four-point Likert scale and the total score for each scale ranges from 0 to 21, with higher scores indicating more psychological distress.

Chemotherapy-induced peripheral neuropathy

The sensory scale of the European Organization for Research and Treatment of Cancer Quality of life Questionnaire Chemotherapy-Induced Peripheral Neuropathy 20 (EORTC QLQ-CIPN20) [18] was used to assess chemotherapy-induced peripheral neuropathy. Respondents are asked to indicate how often they had experienced the specific symptom in the past week. Items are answered on a four-point Likert scale ranging from (1) not at all to (4) very much. In the previous PROFILES study using the same sample as the current study [5], we found that survivors treated with chemotherapy only reported more shooting/burning pain, numbness, and tingling compared to survivors not treated with chemotherapy. On all other EORTC QLQ-CIPN20 items, there were no differences between the two groups. Therefore, we will only focus on these three symptoms, as we are specifically interested in peripheral neuropathy caused by chemotherapy.

Painful CIPN was assessed using the items on shooting or burning pain in the (1) fingers or hands and (2) toes or feet. If survivors answered at least one of the items with “quite a bit” or “very much,” painful CIPN was considered to be present. The items on (1) tingling fingers or hands, (2) tingling toes or feet, (3) numbness in fingers or hands, and (4) numbness in toes or feet were grouped together as an assessment of non-painful CIPN and considered to be present if survivors answered at least one of these items with “quite a bit” or “very much.” Finally, survivors who did not report painful or non-painful CIPN were considered to have “no sensory CIPN.”

Health-related quality of life

The EORTC-QLQ-C30 (version 3.0) was used to assess HRQoL [19]. In this study, only the five functioning scales (i.e., physical, role, cognitive, emotional, and social functioning) and the global health status quality of life scale were used. Items are scored on a four-point Likert scale, which ranges from (1) not at all to (4) very much, except for the global quality of life scale, which ranges from (1) very poor to (7) excellent. Scores were linearly transformed to a 0–100 scale [20], with higher scores indicating a better functioning and better quality of life.

Statistical analyses

NCR data on sociodemographic and clinical characteristics enabled us to compare respondents, non-respondents, and those with unverifiable addresses, using t-tests for continuous variables and chi-square (or Fisher’s exact) tests for categorical variables. In further analyses, only chemotherapy-treated survivors were included, as we are specifically interested in chemotherapy-induced peripheral neuropathy.

Using either t-tests or analyses of variance for continuous variables and chi-square tests for categorical variables, sociodemographic and clinical characteristics were compared between (1) survivors with painful CIPN either with or without non-painful CIPN, (2) survivors with non-painful CIPN only, and (3) survivors without any sensory CIPN.

Spearman’s correlation analysis was used to test the correlation between painful CIPN and non-painful CIPN within hands and feet, for numbness and tingling separately. Then, multivariate logistic regression analyses were conducted to identify sociodemographic, clinical, and psychological characteristics that were associated with painful CIPN and non-painful CIPN. The small number of survivors with painful CIPN did not permit us to include all a priori defined factors in the analyses. Therefore, factors were included based upon significant differences between survivors with painful CIPN, either with or without non-painful CIPN, survivors with non-painful CIPN only, and survivors without any sensory CIPN. Analyses in which age, sex, diabetes mellitus, and rheumatoid arthritis were also included yielded no other significant findings.

Finally, using analysis of covariance, EORTC QLQ-C30 mean scores were compared between (1) survivors with painful CIPN, either with or without non-painful CIPN, (2) survivors with non-painful CIPN only, and (3) survivors without any sensory CIPN. Confounding background variables included for adjustment were determined a priori and chosen to be age at time of questionnaire, sex, years since diagnosis, partner status, stage, number of comorbid conditions, diabetes mellitus, rheumatoid arthritis, osteoarthritis, and cancer type. Sensitivity analyses were then conducted to first compare survivors with numbness to those with tingling to examine whether numbness and tingling can indeed be evaluated together when looking at the impact on HRQoL. Secondly, survivors with painful CIPN only were compared to survivors with non-painful CIPN only. This was done to examine whether any found difference between painful CIPN, with or without non-painful CIPN, versus non-painful CIPN only, can be explained by the difference in symptom experience, or by the burden of experiencing multiple symptoms. Given the small sample size, this analysis was only corrected for age at time of diagnosis, years since diagnosis, number of comorbid conditions, and cancer stage. Clinically important differences were determined using the EORTC QLQ-C30 guidelines as proposed by Cocks et al. [21]. For example, for the “global
quality of life” scale, a mean difference of 4–10 points, 10–15 points, and > 15 points is, respectively, considered a small, medium, and large clinically important difference.

All tests were two-sided and considered to be significant if \( p < 0.05 \). All statistical analyses were performed using SPSS 22 (IBM SPSS Statistics for Windows, Version 22.0 Armonk, NY: IBM Corps USA).

**Results**

**Sample characteristics**

For this study, data collected during the second data wave of a study among CRC survivors was used, which had a response rate of 83% (\( n = 1643 \)). No differences in sociodemographic and clinical characteristics between respondents, non-respondents, and those with non-verifyable addresses were found (data not shown). Among survivors who were treated with chemotherapy (\( n = 500, 30\% \)), data on painful CIPN and non-painful CIPN were available for 477 survivors.

CRC survivors with painful CIPN (\( n = 44, 9\% \)) were diagnosed more recently and reported more anxiety and depressive symptoms compared to survivors without any sensory CIPN (\( n = 362, 76\% \)) (Table 1). No differences in characteristics were found between survivors with painful CIPN and survivors with non-painful CIPN only (\( n = 70, 15\% \)). Finally, compared to survivors who reported having neither painful nor non-painful CIPN, those with non-painful CIPN only were diagnosed more recently, more often diagnosed with colon cancer instead of rectal cancer, more often treated with radiotherapy, and they had a lower disease stage at diagnosis. Furthermore, they more often reported having osteoarthritis and they reported more anxiety symptoms.

**Relationship between painful CIPN and non-painful CIPN**

Of the 477 survivors with data on painful CIPN and non-painful CIPN, 103 survivors (22%) reported non-painful CIPN, irrespective of having painful CIPN or not (Table 2). Painful CIPN was reported by 45 survivors (9%), of which 25% (\( n = 11 \)) reported painful CIPN only and 75% (\( n = 33 \)) reported both painful and non-painful CIPN. In addition, one survivor reported painful CIPN but had missing data on non-painful CIPN.

Moderate correlations were observed between numbness and tingling within hands (\( r_s = 0.53 \)) and within feet (\( r_s = 0.63 \)). The correlations between shooting/burning pain and either numbness (\( r_s = 0.37 \) and \( r_s = 0.40 \)) or tingling (\( r_s = 0.37 \) and \( r_s = 0.45 \)) were weaker, both within hands and feet, respectively.

**Correlates of painful CIPN and non-painful CIPN**

Identifying sociodemographic, clinical, and psychological factors independently associated with painful CIPN revealed that only a longer time since diagnosis was related to a decreased risk of reporting painful CIPN (Table 3). Painful CIPN was reported by 13% (\( n = 29 \)) of survivors diagnosed 4–6 years ago, 6% (\( n = 4 \)) of those diagnosed 6–8 years ago, 4% (\( n = 3 \)) of those diagnosed 8–10 years ago, and 2% (\( n = 1 \)) of those diagnosed 10–12 years ago.

For non-painful CIPN, a higher disease stage (i.e., stage III/IV vs. I and II), osteoarthritis, and more anxiety symptoms were associated with an increased risk, while a longer time since diagnosis was associated with a decreased risk of having non-painful CIPN. Non-painful CIPN was reported by 31% (\( n = 67 \)) of survivors diagnosed 4–6 years ago, 26% (\( n = 21 \)) of those diagnosed 6–8 years ago, 13% (\( n = 8 \)) of those diagnosed 8–10 years ago, and 8% (\( n = 6 \)) of those diagnosed 10–12 years ago.

**Associations with health-related quality of life**

Among chemotherapy-treated CRC survivors, those with painful CIPN reported worse global quality of life and worse physical, role, cognitive, and social functioning compared to both survivors with non-painful CIPN and survivors without any sensory CIPN. All differences were of medium clinical relevance, except for the difference in role functioning between survivors with painful CIPN and those with non-painful CIPN, which was of small clinical relevance, and the difference in cognitive functioning between survivors with painful CIPN and those without any sensory CIPN, which was of large clinical relevance. No differences were found in emotional functioning. Also, no significant differences were observed between survivors with non-painful CIPN only and those without any sensory CIPN (Fig. 1).

Sensitivity analyses were conducted to first compare survivors with numbness (\( n = 8 \)) and those with tingling (\( n = 36 \)) (e.g., mean physical functioning = 91 vs. 82, respectively). No differences between these two groups were found in global quality of life or any of the functional scales (not formally tested because of small numbers).

Second, survivors with painful CIPN only (\( n = 11 \)) were compared to survivors with non-painful CIPN only (\( n = 70 \)). Survivors who experienced painful CIPN reported worse physical (55 vs. 82, \( p = 0.002 \)), role (55 vs. 78, \( p = 0.01 \)), and social (67 vs. 87, \( p = 0.003 \)) functioning compared to those with non-painful CIPN only. The difference in role functioning was of medium clinical relevance, while the difference in physical and social functioning were of large clinical relevance. Finally, no differences in global quality of life (61 vs. 76, \( p = 0.05 \)), emotional (77 vs. 82, \( p = 0.72 \)), or cognitive functioning (65 vs. 81, \( p = 0.09 \)) were observed.
Table 1: Sociodemographic and clinical characteristics of the chemotherapy-treated colorectal cancer survivors stratified by chemotherapy-induced peripheral neuropathy symptoms.

|                          | CRC survivors with painful CIPN<sup>a</sup> (n = 45, 9%) | CRC survivors with non-painful CIPN only (n = 70, 15%) | CRC survivors without any sensory CIPN symptoms (n = 362, 76%) | p value<sup>b</sup> |
|--------------------------|----------------------------------------------------------|--------------------------------------------------------|-------------------------------------------------------------|--------------------|
| Age at time of survey (mean (SD)) | 65.9 (8.9)                                               | 66.1 (8.6)                                              | 66.6 (10.1)                                                 | 0.91               |
| Sex (female)             | 21 (47%)                                                 | 26 (37%)                                               | 152 (42%)                                                   | 0.31               |
| Partner (yes)            | 39 (87%)                                                 | 61 (87%)                                               | 292 (81%)                                                   | 0.94               |
| Educational level<sup>c</sup> |                                                        |                                                        |                                                             | 0.54               |
| Low                      | 8 (18%)                                                  | 8 (11%)                                                | 48 (13%)                                                    |                    |
| Middle                   | 26 (59%)                                                 | 42 (60%)                                               | 222 (62%)                                                   |                    |
| High                     | 10 (23%)                                                 | 20 (29%)                                               | 91 (25%)                                                    |                    |
| Employed (yes)           | 7 (16%)                                                  | 19 (27%)                                               | 85 (24%)                                                    | 0.16               |
| Number of comorbid conditions |                                                          |                                                        |                                                             | 0.85               |
| None                     | 7 (16%)                                                  | 13 (20%)                                               | 108 (32%)                                                   |                    |
| One                      | 15 (35%)                                                 | 24 (36%)                                               | 112 (33%)                                                   |                    |
| Two or more              | 21 (49%)                                                 | 29 (44%)                                               | 117 (35%)                                                   |                    |
| Tumor location           |                                                        |                                                        |                                                             | 0.64               |
| Colon                    | 33 (73%)                                                 | 54 (77%)<sup>*</sup>                                   | 228 (63%)                                                   |                    |
| Rectal                   | 12 (27%)                                                 | 16 (23%)                                               | 134 (37%)                                                   |                    |
| Years since diagnosis    |                                                        |                                                        |                                                             | 0.47               |
| Mean (SD)                | 4.4 (2.0)<sup>***</sup>                                 | 4.1 (1.7)<sup>***</sup>                                | 6.0 (2.8)                                                   |                    |
| Range                    | 2–11                                                     | 2–9                                                    | 2–12                                                       | 0.22               |
| TNM stage                |                                                        |                                                        |                                                             |                    |
| I                        | 2 (4%)                                                   | 0 (0%)<sup>*</sup>                                     | 24 (7%)                                                     |                    |
| II                       | 4 (9%)                                                   | 5 (7%)                                                 | 59 (16%)                                                    |                    |
| III                      | 33 (73%)                                                 | 58 (83%)                                               | 242 (67%)                                                   |                    |
| IV                       | 6 (13%)                                                  | 5 (7%)                                                 | 26 (7%)                                                     |                    |
| Unknown                  | 0 (0%)                                                   | 2 (3%)                                                 | 11 (3%)                                                     |                    |
| Tumor differentiation grade |                                                        |                                                        |                                                             | 0.80               |
| Well differentiated       | 5 (11%)                                                  | 6 (9%)                                                 | 34 (9%)                                                     |                    |
| Moderately differentiated | 29 (64%)                                                 | 41 (59%)                                               | 220 (61%)                                                   |                    |
| Poorly differentiated     | 6 (13%)                                                  | 12 (17%)                                               | 47 (13%)                                                    |                    |
| Unknown                  | 5 (11%)                                                  | 11 (15%)                                               | 61 (17%)                                                    |                    |
| Radiotherapy (yes)       | 9 (20%)                                                  | 11 (16%)<sup>**</sup>                                  | 116 (32%)                                                   |                    |
| Comorbidities associated with PN-like symptoms<sup>d</sup> |                                                        |                                                        |                                                             | 0.55               |
| Diabetes mellitus        | 6 (14%)                                                  | 8 (12%)                                                | 51 (15%)                                                    | 0.78               |
| Rheumatoid arthritis     | 3 (7%)                                                   | 3 (5%)                                                 | 21 (6%)                                                     | 0.68               |
| Osteoarthritis           | 10 (23%)<sup>*</sup>                                    | 23 (35%)<sup>*</sup>                                   | 70 (21%)                                                    | 0.20               |
| Anxiety (mean (SD))      | 5.8 (4.2)<sup>*</sup>                                    | 5.7 (4.0)<sup>**</sup>                                  | 4.3 (3.5)                                                   | 0.88               |
| Depression (mean (SD))   | 5.6 (4.2)<sup>*</sup>                                    | 4.7 (3.4)                                              | 4.2 (3.6)                                                   | 0.21               |

Some variables exceed 100% due to rounding off.

CIPN, chemotherapy-induced peripheral neuropathy; SD, standard deviation

<sup>a</sup> CIPN survivors with painful CIPN were either with or without non-painful CIPN

<sup>b</sup> P values represent differences between CRC survivors with painful CIPN, either with or without non-painful CIPN, versus CRC survivors with non-painful CIPN only

<sup>c</sup> Education: low (no or primary school); medium (lower general secondary education or vocational training); high (pre-university education, high vocational training, university)

<sup>d</sup> Most frequent comorbidities associated with peripheral neuropathy

<sup>*</sup>p < 0.05  **p < 0.01  ***p < 0.001; p value represents difference between either CRC survivors with painful CIPN or CRC survivors with non-painful CIPN only versus CRC survivors without these symptoms
Table 2  Presence of painful and non-painful CIPN in chemotherapy-treated colorectal cancer survivors

|                  | Painful CIPN (No) | Painful CIPN (Yes) | Total |
|------------------|-------------------|-------------------|-------|
| Non-painful CIPN | 362 (76%)         | 11 (2%)           | 373   |
|                   | 70 (15%)          | 33 (7%)           | 103   |
| Total             | 432               | 44                | 476   |

CIPN, chemotherapy-induced peripheral neuropathy
*C One CRC survivor reported painful CIPN but had missing data on non-painful CIPN

Discussion

In this secondary analysis of a study among long-term CRC survivors, we showed that the majority of survivors who reported painful CIPN, also reported non-painful CIPN, while having only painful CIPN was much less common. The prevalence of both painful and non-painful CIPN found in this study is comparable to the prevalence (9% and 26%, respectively) found in a previous study among CRC patients [13]. As the CRC survivors in this study were on average 5.6 years after diagnosis, this shows that both painful and non-painful CIPN are chronic problems that occur in a large number of CRC patients after chemotherapy.

Regarding the correlates of painful CIPN, only a longer time since diagnosis was significantly associated with a decreased risk, indicating that painful CIPN fades or even disappears over time in most patients. For non-painful CIPN, several correlates were found. First, a longer time since diagnosis was also associated with a decreased risk of non-painful CIPN. In addition, a higher disease stage, osteoarthritis, and more anxiety symptoms were associated with an increased risk of non-painful CIPN. The finding that osteoarthritis was a significant correlate is most likely because pain, numbness, and tingling are also frequently reported symptoms in that condition. Regarding anxiety, several other studies also found an association between anxiety and CIPN [12, 22–25]. As the current study is cross-sectional, we cannot draw conclusions on the direction of this association. It could be that CIPN symptoms result in more anxiety, due to the pain and limitations in daily functioning [26]. However, two previous studies found that pre-treatment anxiety was associated with neuropathic symptoms, but not to pain in hands or feet [12], and persistent CIPN [25]. A psychological explanation could be that people who are anxious often develop a catastrophic thinking style and that catastrophizing and anxiety sensitivity could be a common vulnerability factor for chronic CIPN [27]. Pro-inflammatory cytokines may offer a biological explanation, as they have been linked to both anxiety and CIPN [28, 29]. Also, recovery from the nerve injury in CIPN could be slowed down by the pro-inflammatory cytokines that are produced due to the anxiety. In addition, inflammatory mediators (produced due to anxiety) can contribute to hypersensitivity through stimulation or potentiation of nociceptive transduction at peripheral terminals and central changes [30].

In this study, the association between (non-)painful CIPN and HRQoL was also examined. We found that painful CIPN was related to a worse HRQoL compared to those with non-painful CIPN only and those with no sensory CIPN. This finding is in line with prior studies done in diabetes research [11]. In the previously mentioned study among CRC patients, only non-painful CIPN was associated with higher odds of having poor HRQoL at baseline, while only painful CIPN was associated with declining HRQoL assessed 4–5 weeks later [13]. In our study, no differences in HRQoL were found between survivors with non-painful CIPN only and those without sensory CIPN. It should be noted that, while survivors in the “no sensory CIPN” group did not report painful or non-painful (i.e., numbness and tingling) CIPN, they could still experience neuropathy symptoms, as we did not exclude those who reported other neuropathy symptoms measured by the CIPN20. However, as one of our previous studies using the same sample [5] showed no differences between survivors with and without chemotherapy on any of these symptoms, the findings regarding HRQoL among those with non-painful CIPN20 are likely explained by the fact that CIPN is a chronic condition that can appear over time in most patients. For non-painful CIPN, a higher disease stage, osteoarthritis, and more anxiety symptoms were associated with a decreased risk of non-painful CIPN. The finding that osteoarthritis was a significant correlate is most likely because pain, numbness, and tingling are also frequently reported symptoms in that condition. Regarding anxiety, several other studies also found an association between anxiety and CIPN [12, 22–25]. As the current study is cross-sectional, we cannot draw conclusions on the direction of this association. It could be that CIPN symptoms result in more anxiety, due to the pain and limitations in daily functioning [26]. However, two previous studies found that pre-treatment anxiety was associated with neuropathic symptoms, but not to pain in hands or feet [12], and persistent CIPN [25]. A psychological explanation could be that people who are anxious often develop a catastrophic thinking style and that catastrophizing and anxiety sensitivity could be a common vulnerability factor for chronic CIPN [27]. Pro-inflammatory cytokines may offer a biological explanation, as they have been linked to both anxiety and CIPN [28, 29]. Also, recovery from the nerve injury in CIPN could be slowed down by the pro-inflammatory cytokines that are produced due to the anxiety. In addition, inflammatory mediators (produced due to anxiety) can contribute to hypersensitivity through stimulation or potentiation of nociceptive transduction at peripheral terminals and central changes [30].

In this study, the association between (non-)painful CIPN and HRQoL was also examined. We found that painful CIPN was related to a worse HRQoL compared to those with non-painful CIPN only and those with no sensory CIPN. This finding is in line with prior studies done in diabetes research [11]. In the previously mentioned study among CRC patients, only non-painful CIPN was associated with higher odds of having poor HRQoL at baseline, while only painful CIPN was associated with declining HRQoL assessed 4–5 weeks later [13]. In our study, no differences in HRQoL were found between survivors with non-painful CIPN only and those without sensory CIPN. It should be noted that, while survivors in the “no sensory CIPN” group did not report painful or non-painful (i.e., numbness and tingling) CIPN, they could still experience neuropathy symptoms, as we did not exclude those who reported other neuropathy symptoms measured by the CIPN20. However, as one of our previous studies using the same sample [5] showed no differences between survivors with and without chemotherapy on any of these symptoms, the findings regarding HRQoL among those with non-painful CIPN20 are likely explained by the fact that CIPN is a chronic condition that can appear over time in most patients.

Table 3  Correlates of painful and non-painful chemotherapy-induced peripheral neuropathy (CIPN) vs. no sensory CIPN in colorectal cancer survivors

|                                      | Painful CIPN | Non-painful CIPN |
|--------------------------------------|--------------|------------------|
|                                      | OR (95% CI)  | P value          |
|                                      |              |                  |
| Years since diagnosis                | 0.78 (0.67–0.91) | 0.001 |
| Cancer stage (III and IV vs. I and II)| 1.78 (0.67–4.86) | 0.26  |
| Tumor type (rectal)                  | 1.46 (0.45–4.71) | 0.53  |
| Osteoarthritis (yes)                 | 1.16 (0.52–2.56) | 0.72  |
| Radiotherapy (yes)                   | 0.54 (0.14–2.03) | 0.36  |
| Anxiety                              | 1.06 (0.95–1.19) | 0.29  |
| Depression                           | 1.05 (0.94–1.17) | 0.39  |

CIPN, chemotherapy-induced peripheral neuropathy; OR, odds ratio; 95% CI, 95% confidence interval
CIPN most likely indicate that they have a similar HRQoL to those who have neuropathy symptoms related to normal aging [31] and cancer itself [32].

While painful CIPN has a large impact on HRQoL, there are few effective treatments for it. Duloxetine is currently the only drug that has shown to be effective in the treatment of painful CIPN [33]. Anticonvulsants and other antidepressants, which have shown their efficacy in other neuropathic pain populations, are also used to treat CIPN. However, given the side effects and lack of efficacy, adherence is often poor [34]. Cognitive-behavioral therapy (CBT) might also improve HRQoL in patients with neuropathic pain [35]. A recent pilot study tested the effectiveness of a self-guided online CBT for painful CIPN, with promising results [36]. However, as the development of (severe) CIPN during chemotherapy often leads to a reduction in chemotherapy doses, or even cessation of treatment [3], it also seems crucial for future studies to focus more on the prevention of CIPN.

Several limitations of our study need to be acknowledged. First, we do not have information on the presence of neuropathy symptoms (e.g., idiopathic or entrapment neuropathy) before chemotherapy. While we did control for diabetes, rheumatoid arthritis, and osteoarthritis, which could lead to neuropathy-like symptoms, we cannot be certain that the neuropathy symptoms assessed in this study were caused by the chemotherapy. We also did not have any information on the type of chemotherapeutic agent, number of chemotherapy cycles, and possible dose reduction, while it is known that CIPN depends on these factors and thereby could have impacted HRQoL [3]. Therefore, to be able to make recommendations on treatment decisions and alterations to reduce painful CIPN, future studies should include these measures. It should be noted that oxaliplatin, a chemotherapeutic agent often associated with CIPN [37], has been used since 2007, which is the last 2 years of our study period. This could be a confounder when looking at the prevalence of (non-)painful CIPN in our study. Another limitation is that we did not perform a clinician-based assessment of CIPN, while it was concluded in a recent review on the clinical assessment tools for CIPN that patient-reported assessments of CIPN should be combined with clinician-rated neurological assessment tools to be able to give a clear picture of neuropathy [38]. Also, given the rather low sample size of survivors with painful CIPN, we could not include many possible correlates. It could be that important factors not included in the analysis are associated with painful CIPN. Furthermore, some factors that were included in the analysis, particularly those significant in non-painful CIPN, might have been significant within a larger sample. Consequently, the question remains whether there are correlates that apply to both painful and non-painful CIPN or whether there are correlates that are unique to painful CIPN (or non-painful CIPN), making it possible to distinguish between the two. Therefore, in future research, a larger sample should be included so a more thorough examination of the differences between subgroups (i.e., patients with painful CIPN only, patients with both painful and non-painful CIPN, and patients with non-painful CIPN only) can be done. Finally, it should be acknowledged that we did not correct for multiple testing, thereby increasing the potential for false positive findings.

Despite these limitations, this is, to the best of our knowledge, the first study that has examined the prevalence,
correlates, and impact of painful versus non-painful CIPN on HRQoL among long-term CRC survivors. The findings of this study indicate that painful CIPN must be distinguished from other CIPN symptoms, such as non-painful CIPN, given the large impact on HRQoL. Therefore, patients should be informed about the relationship between painful CIPN and HRQoL. Moreover, patients should also be screened specifically on painful CIPN, as treatment options, while limited, are available for painful CIPN. Finally, the question remains whether painful CIPN should be distinguished from non-painful CIPN when looking at predictors, mechanisms and therefore also possible treatment.

**Acknowledgements** We thank all patients and their physicians for their participation in the study. Special thanks goes to M. van Bommel, MD, who was willing to function as an independent advisor and to answer questions of patients. In addition, we want to thank the following hospitals for their cooperation: Amphia Hospital, Breda; Bernhoven Hospital, Veghel and Oss; Catharina hospital, Eindhoven; Elkerliek Hospital, Helmond;
Jeroen Bosch hospital, ’s Hertogenbosch; Maxima Medical Centre, Eindhoven and Veldhoven; Sint Anna hospital, Geldrop; Elisabeth Tweesteden hospital; VieCuri hospital, Venlo and Venray.

**Compliance with ethical standards**

**Conflict of interest** The authors declare that they have no conflict of interest.

The authors have full control of all primary data and we allow the journal to review our data if requested.

**Ethical approval** This study was approved by a certified medical ethics committee.

**Statement of informed consent** All patients signed informed consent.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Bujanda L, Sarasqueta C, Hijona E, Hijona L, Cosme A, Gil I, Elorza JL, Asensio JI, Larburn S, Enrquez-Navascués JM, Jover R, Balague F, Llor X, Bessa X, Andreu M, Paya A, Castells A. Gastrointestinal Oncology Group of the Spanish Gastroenterological Association (2010) Colorectal cancer prognosis twenty years later. World J Gastroenterol 16(7):862–867
2. Brewer JR, Morrison G, Dolan ME, Fleming GF (2016) Chemotherapy-induced peripheral neuropathy: current status and progress. Gynecol Oncol 140(1):176–183
3. Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod M, Colvin LA, Fallon M (2014) Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 155(12):2461–2470
4. Ezendam NP, Pijlman B, Bhugwandin C, Pruitt JF, Mols F, Vos MC, Pijnenborg JM, van de Poll-Franse L (2014) Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer survivors: results from the population-based PROF1LES registry. Gynecol Oncol 135(3):510–517
5. Mols F, Beijers T, Lemmens V, van den Hurk C, Vreugdenhil G, van de Poll-Franse L (2013) Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROF1LES registry. J Clin Oncol 31(21):2699–2707
6. Liu H, et al. (2015) Comparing and Validating Simple Measures of Patient-Reported Peripheral Neuropathy for Oncology Clinical Trials: NCCTG N0897 (Alliance) A Pooled Analysis of 2440 Patients. SOJ Anesthesiol Pain Manag, 2(2)
7. Wolf SL, Barton DL, Qin R, Wos EJ, Sloan JA, Liu H, Aaronson NK, Satle DV, Mattar BI, Green NB, Loprinzi CL (2012) The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA. Support Care Cancer 20(3):625–632
8. Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, Kamal A, Le-Lindqwister NA, Soori GS, Jasloskki AJ, Kelaghan J, Novotny PJ, Lachance DH, Loprinzi CL (2012) Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: north central cancer treatment group trial N08C1. Cancer 118(20):5171–5178
9. Tesfaye S, Vileikyte L, Rayman G, Sindrup SH, Perkins BA, Baconia M, Vinik AL, Boulton AJ, Toronto Expert Panel on Diabetic Neuropathy (2011) Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev 27(7):629–638
10. Abbott CA, Malik RA, van Ross E, Kulkarni J, Boulton AJ (2011) Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care 34(10):2220–2224
11. Van Acker K et al (2009) Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab 35(3):206–213
12. Ventzel L, Jensen AB, Jensen AR, Jensen TS, Finnerup NB (2016) Chemotherapy-induced pain and neuropathy: a prospective study in patients treated with adjuvant oxaliplatin or docetaxel. Pain 157(3):560–568
13. Jones D, Zhao F, Brell J, Lewis MA, Loprinzi CL, Weiss M, Fisch MJ (2015) Neuropathic symptoms, quality of life, and clinician perception of patient care in medical oncology outpatients with colorectal, breast, lung, and prostate cancer. J Cancer Surviv 9(1):1–10
14. Janssen-Heijnen MLG et al (2005) Results of 50 years cancer registry in the south of the Netherlands: 1955–2004 (in Dutch). Eindhoven Cancer Registry, Eindhoven
15. van de Poll-Franse LV et al (2011) The patient reported outcomes following initial treatment and long term evaluation of survivorship registry: scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts. Eur J Cancer 47(14):2188–2194
16. Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN (2003) The self-administered comorbidity questionnaire: a new method to
assess comorbidity for clinical and health services research. Arthritis Rheum 49(2):156–163

17. Zigmund AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67(6):361–370

18. Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrandt JG, Delattre JY, Hoang-Xuan K, Lanteri-Minet M, Grant R, Huddart R, Moynihan C, Maher J, Lucey R, EORTC Quality of Life Group (2005) The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 41(8):1135–1139

19. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtnier H, Fleishman SB, de Haes JC (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376

20. Fayers PM, et al. (2001) EORTC QLQ-C30 scoring manual

21. Cocks K, King MT, Velikova G, Martyn St-James M, Fayers PM, et al. (2001) EORTC QLQ-C30 scoring manual

22. Bao T, Basal C, Seluzicki C, Li SQ, Seidman AD, Mao JJ (2016) Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk. Breast Cancer Res Treat 159(2):327–333

23. Bonhof CS, van de Poll-Franse L, Vissers PAJ, Wasowicz DK, Wegdam JA, Révézé D, Vreugdenhil G, Mols F (2019) Anxiety and depression mediate the association between chemotherapy-induced peripheral neuropathy and fatigue: results from the population-based PROFILES registry. Psychoneuroendocrinology 28(9):1926–1933

24. Hong JS, Tian J, Wu LH (2014) The influence of chemotherapy-induced neurotoxicity on psychological distress and sleep disturbance in cancer patients. Curr Oncol 21(4):174–180

25. Lee KM, Jung D, Hwang H, Son KL, Kim TY, Im SA, Lee KH, Hahn BJ (2018) Pre-treatment anxiety is associated with persistent chemotherapy-induced peripheral neuropathy in women treated with neo-adjuvant chemotherapy for breast cancer. J Psychosom Res 108:14–19

26. Bakitas MA (2007) Background noise: the experience of chemotherapy-induced peripheral neuropathy. Nurs Res 56(5):323–331

27. Goodin BR, McGuire L, Stapleton LM, Quinn NB, Fabian LA, Haythornthwaite JA, Edwards RK (2009) Pain catastrophizing mediates the relationship between self-reported strenuous exercise involvement and pain ratings: moderating role of anxiety sensitivity. Psychosom Med 71(9):1018–1025

28. O'Donovan A et al (2010) Clinical anxiety, cortisol and interleukin-6: evidence for specificity in emotion-biology relationships. Brain Behav Immun 24(7):1074–1077

29. Starkweather A (2010) Increased interleukin-6 activity associated with painful chemotherapy-induced peripheral neuropathy in women after breast cancer treatment. Nurs Res Pract 2010:281531

30. Levine JD, Reiling DB (1999) In: Wall PD, Melzack R (eds) Peripheral mechanisms of inflammatory pain, in Textbook of pain. Churchill Livingstone, New York, pp 59–84

31. Mols F, van de Poll-Franse L, Vreugdenhil G, Beijers AJ, Kieffer JM, Aaronson NK, Hussun O (2016) Reference data of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 Questionnaire in the general Dutch population. Eur J Cancer 69:28–38

32. Boyette-Davis JA, Eng C, Wang XS, Cleeland CS, Wendelschaef-Crab G, Kennedy WR, Simone DA, Zhang H, Dougherty PM (2012) Subclinical peripheral neuropathy is a common finding in colorectal cancer patients prior to chemotherapy. Clin Cancer Res 18(11):3180–3187

33. Smith EM, Pang H, Cirincione C, Fleishman S, Paskett ED, Ahles T, Bressler LR, Fadul CE, Knox C, Le-Lindqwister N, Gilman PB, Shapiro CL, Alliance for Clinical Trials in Oncology (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. Jama 309(13):1359–1367

34. Gharibian D, Polzin JK, Rho JP (2013) Compliance and persistence of antidepressants versus anticonvulsants in patients with neuropathic pain during the first year of therapy. Clin J Pain 29(5):377–381

35. Wetering EJ, Lennens KM, Nieboer AP, Huijsman R (2010) Cognitive and behavioral interventions for the management of chronic neuropathic pain in adults—a systematic review. Eur J Pain 14(7):670–681

36. Knoerl R, Smith EML, Barton DL, Williams DA, Holden JE, Krauss JC, LaVasseur B (2018) Self-guided online cognitive behavioral strategies for chemotherapy-induced peripheral neuropathy: a multicenter, pilot, randomized, Wait-List Controlled Trial. J Pain 19(4):382–394

37. Beijers AJM et al (2015) Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry. Acta Oncol 54(4):463–469

38. Park SB et al (2019) Overview and critical revision of clinical assessment tools in chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst 24(Suppl 2):S13–S25

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.